Finding new treatments for lung cancer by targeting NSD3
Official title: Screening for inhibitors of NSD3 as a treatment for lung cancer
Funded at University of Michigan at Ann Arbor · NIH-11015921 · Data updated 2026-11-12
This study is looking for new medicines that can help fight aggressive lung cancer by blocking a protein called NSD3, and if successful, it could offer better treatment options for patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $481,033 |
| NIH project number | 5R01CA276074-03 |
| Project ID | NIH-11015921 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung squamous cell carcinoma or other cancers associated with NSD3 amplification.
✕Less likely to help
Patients with lung cancer types not associated with NSD3 or those who do not have a confirmed diagnosis of cancer may not benefit from this research.
What this research studies
This research focuses on developing small molecule inhibitors that target the NSD3 protein, which has been linked to aggressive forms of lung cancer, particularly lung squamous cell carcinoma. The approach involves high throughput screening to identify potential inhibitors that can block the activity of NSD3, which is known to contribute to cancer progression. Patients may benefit from new therapeutic options if these inhibitors prove effective in treating lung cancer. The research utilizes advanced biochemical techniques to validate the effectiveness of these inhibitors in laboratory settings.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with lung cancer, particularly those with aggressive forms linked to NSD3.
How similar studies have gone: While the specific inhibitors for NSD3 are novel and have not been reported before, similar approaches targeting oncogenes have shown promise in other cancer treatments.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Grembecka, Jolanta — University of Michigan at Ann Arbor
- Study coordinator: Grembecka, Jolanta
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.